Drug Trial Radar · NCT04745689
Study of AZD2811 + Durvalumab in ES-SCLC
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
31
Actual
Start
Feb 23, 2021
Primary completion
Jun 18, 2022
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.
Conditions
- Small-Cell Lung Cancer
Interventions
DurvalumabDrug
IV infusions through induction phase. IV infusions through maintenance phase until PD or other discontinuation criteria.
AZD2811Drug
IV infusions through maintenance phase until PD or other discontinuation criteria.
CarboplatinDrug
IV infusions through induction phase if chosen by Investigator.
CisplatinDrug
IV infusions through induction phase if chosen by Investigator.
EtoposideDrug
IV infusions through induction phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maintenance Participants Alive and Progression Free (APF12) Per RECIST 1.1 [Efficacy]Time frame: Up to 12 months
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Grand Rapids, Michigan
Research Site
Bydgoszcz, Poland
Research Site
Olsztyn, Poland
Research Site
Poznan, Poland
Research Site
Cheongju-si, South Korea
Research Site
Jinju, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seville, Spain
Research Site
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.